However, the CD4+ T cell–depleted mice showed a partial response that suggests a secondary role of CD4+ T cells in the overall antitumor response to RPE-mIL2 in ovarian cancer mice (Fig. 4, F and G). Here, CD4 is linked to ovarian carcinoma.